Small-Cell Lung Cancer Therapeutics Development and Professional Review Analysis 2017 adds Exclusive Research on “Small-Cell Lung Cancer – Pipeline Review, H1 2016” reports to its database.


The report provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects.


GET SAMPLE REPORT @                       


Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



– The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer

– The report reviews pipeline therapeutics for Small-Cell Lung Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Small-Cell Lung Cancer therapeutics and enlists all their major and minor projects

– The report assesses Small-Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer


Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Table of Content: Key Points

Table of Contents 2

Introduction 7

Small-Cell Lung Cancer Overview 8

Therapeutics Development 9

Small-Cell Lung Cancer – Therapeutics under Development by Companies 11

Small-Cell Lung Cancer – Therapeutics under Investigation by Universities/Institutes 16

Small-Cell Lung Cancer – Pipeline Products Glance 17

Small-Cell Lung Cancer – Products under Development by Companies 20

Small-Cell Lung Cancer – Products under Investigation by Universities/Institutes 27

Small-Cell Lung Cancer – Companies Involved in Therapeutics Development 28

Small-Cell Lung Cancer – Therapeutics Assessment 100

Drug Profiles 122

Small-Cell Lung Cancer – Recent Pipeline Updates 372

Small-Cell Lung Cancer – Dormant Projects 614

Small-Cell Lung Cancer – Discontinued Products 621

Small-Cell Lung Cancer – Product Development Milestones 623



ACCESS REPORT @                         



Get in touch:




Media Contact
Company Name:
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States